Literature DB >> 3028613

Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line.

J G Zijlstra, E G de Vries, N H Mulder.   

Abstract

In a human small cell lung carcinoma cell line, GLC4, Adriamycin (ADR) resistance was induced. In the resistant cell line, GLC4/ADR, a 45% decreased intracellular ADR level was found compared to GLC4, but this could not fully explain the resistance. Evaluation of DNA damage in both cell lines after incubation with ADR by alkaline and neutral elution revealed single-strand breaks, DNA-protein cross-links, and double-strand breaks (DSB). At all incubation concentrations there was a decreased amount of all types of DNA damage in GLC4/ADR. The number of DSB was decreased also when corrected for the decreased intracellular concentration. This can at least partly be explained by the decreased stability of ADR induced DSB. After removal of ADR, 80% of DSB was repaired in 1 h in GLC4/ADR against no repair in GLC4. X-ray induced DSBs were also repaired faster: in GLC4/ADR t1/2 = 10 min and in GLC4 t1/2 = 23 min. Ratios for single strand breaks/DSBs and single strand breaks/DNA-protein cross-links between GLC4 and GLC4/ADR after exposure to ADR differed; these differences were compatible with differences in the distribution of the various types of DNA damage induced in the cell lines due to an altered ADR-topoisomerase II interaction. In this human small cell lung carcinoma cell line the resistance is multifactorial with decreased intracellular ADR levels, increased DNA repair, and altered ADR-topoisomerase interaction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028613

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  High-copy cDNA amplification of minimal total RNA quantities for gene expression analyses.

Authors:  H Schwabe; U Stein; W Walther
Journal:  Mol Biotechnol       Date:  2000-02       Impact factor: 2.695

2.  Establishment of two new multi-drug resistant variants of the human tumor line Hep-2.

Authors:  A Redmond; E Law; U Gilvarry; M Clynes
Journal:  Cell Biol Toxicol       Date:  1990-07       Impact factor: 6.691

3.  ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter.

Authors:  S Paul; L M Breuninger; K D Tew; H Shen; G D Kruh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 4.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

Review 5.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

6.  Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues.

Authors:  A B Schroeijers; G L Scheffer; M J Flens; G A Meijer; M A Izquierdo; P van der Valk; R J Scheper
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

7.  Analysis of cell type-specific responses mediated by the type IV secretion system of Helicobacter pylori.

Authors:  Bianca Bauer; Stefan Moese; Sina Bartfeld; Thomas F Meyer; Matthias Selbach
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.

Authors:  M Müller; C Meijer; G J Zaman; P Borst; R J Scheper; N H Mulder; E G de Vries; P L Jansen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

9.  Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.

Authors:  Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Methods Mol Biol       Date:  2010

10.  Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.

Authors:  S de Jong; J G Zijlstra; N H Mulder; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.